Publications by authors named "Kimberly Holmquist"
Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study.
JMIR Public Health Surveill
June 2024
Article Synopsis
- The study analyzed the potential link between bivalent COVID-19 vaccination and the incidence of ischemic stroke, focusing on individuals aged 12 and older within a specific time frame in a large health care system.
- Results indicated no increased risk of ischemic stroke within 21 days of vaccination for either the Pfizer-BioNTech or Moderna vaccines across most groups, but a notable increase in risk was found for those under 65 who received the Pfizer-BioNTech vaccine alongside the influenza shot within 42 days.
- For individuals with a prior SARS-CoV-2 infection, the risk of stroke further increased, suggesting a need for close monitoring in these populations after vaccination.
Article Synopsis
- The study examines the safety of 2-dose mRNA vaccines, focusing on serious adverse events (SAEs) during the risk period after the first dose and how they might affect the safety evaluation for the second dose.
- Researchers developed two new methods, propensity score SCCS (PS-SCCS) and partitioned SCCS (P-SCCS), which provided unbiased estimates of the relative incidence of myocarditis/pericarditis after vaccination, unlike standard SCCS which overestimated risk after the second dose.
- Findings indicated that mRNA vaccines, particularly after the second dose, are linked with increased risks of myocarditis/pericarditis in individuals aged 12-39.
Background: Bivalent mRNA COVID-19 vaccines were developed to provide protection against the original SARS-CoV-2 strain and Omicron BA.4/BA.5 variants, but uptake in the United States has been low.
View Article and Find Full Text PDFBackground: COVID-19 vaccination is crucial in combating the COVID-19 pandemic. Messenger RNA COVID-19 vaccines were initially authorized as a 2-dose primary series and have been widely used in the United States; completing the 2-dose primary series offers protection against infection, severe illness, and death. Understanding the risk factors for not completing the 2-dose primary series is critical to evaluate COVID-19 vaccination programs and promote completion of the 2-dose primary series.
View Article and Find Full Text PDFVariants in hereditary cancer risk genes are frequently identified following tumor-based DNA sequencing and represent an opportunity to diagnose hereditary cancer. We implemented an automated hereditary cancer screening program in a large HMO for all patients who underwent tumor-based DNA sequencing to identify patients with hereditary cancer and determine if this approach augmented existing genetic counseling approaches driven by personal/family history criteria. Regular automated searches of a centralized tumor DNA variant database were performed for ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, PALB2, and/or PMS2 variants, and germline hereditary cancer gene panel testing was offered to patients with tumor variants who had never undergone germline testing.
View Article and Find Full Text PDFIn the original article the list of author names and affiliations were incorrect.
View Article and Find Full Text PDFBackground: In 2016, the Patient-Centered Outcomes Research Institute funded the National Patient Centered Clinical Research Network (PCORnet) Bariatric Study (PBS). Understanding the experience of postoperative patients was a key component of this study.
Methods: Nine focus groups were conducted in Southern California, Louisiana, Pennsylvania, and Ohio and in a national advocacy conference for patients with obesity.
Background: Studies have investigated a possible association between family history of HZ and the occurrence of HZ. However, the results were inconclusive and susceptible to bias. We evaluated this association in an elderly population.
View Article and Find Full Text PDF